Insulin secretagogues peptides (incretins) in Diabetes - Clinical Trial Results

Systematic review and meta-analysis of clinical trials about insulin secretagogues peptides (incretins) in diabetes.

Clinical trials enrolled the following type of patients :

all type of patients pdf

obese individuals pdf

See also:

insulin secretagogues peptides (incretins) (all clinical conditions)
diabetes (all therapeutical action or mecanism)
Other insulin secretagogues peptides (incretins): albiglutide , exenatide , liraglutide , lixisenatide , taspoglutide ,

Entry term : Glucose Intolerance, Diabetes Mellitus, Insulin Dependent, Type 1 Diabetes Mellitus, IDDM, Diabetes Mellitus, Type 2, Diabetes Mellitus, Non Insulin Dependent, Type 2 Diabetes Mellitus, NIDDM, diabetic, Incretin, Glucose-Dependent Insulin-Releasing Hormone, Glucagon-Like Peptide 1 agonists, GLP-1 agonists, GLP 1 agonists,

citeULike

This site complies to the HONcode standard for trustworthy health information: verify here.

Last uptaded on 2011/4
95 user(s) connected

TrialResults-center database by TrialResults-center is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France License .

OpenSearch feed - Add TrialResults-center.org to your browser's search bar